Campaign India Team
Jun 17, 2018

Cannes Lions 2018: DDB Mudra, Grey, McCann and TBWA get three shortlists each in Health, Pharma Lions

JWT also in the running with one shortlist

Cannes Lions 2018: DDB Mudra, Grey, McCann and TBWA get three shortlists each in Health, Pharma Lions
The organisers of the Cannes Lions International Festival of Creativity have announced the shortlists for the Health and Wellness, Pharma Lions.
 
Thirteen Indian entries have made the cut.
 
DDB Mudra's 'Project free period' for Johnson & Johnson Stayfree Sanitary Pads has three of them.
 
Grey Group India has three shortlists for 'The health purse (sehat ka batua) for Mahindra Rise.
 
McCann Health New Delhi also has three shortlists, all for 'Noon Assembly' for Kwality Milk.
 
TBWA's three shortlists come in the Pharma Lions for 'Blind to Speak' for Asha Ek Hope Foundation.
 
J Walter Thompson has one shortlist for 'Every Half Counts' for UNICEF.
 
 
 
Source:
Campaign India

Related Articles

Just Published

3 hours ago

Gen AI has created an 'iPhone moment': Coca-Cola's ...

Ahead of Campaign360, Coca-Cola's Matthias Blume explains how the brand continues to grow efficiently while maintaining creative excellence, platform relevance, and meaningful consumer engagement.

3 hours ago

Moves and wins roundup: Week of 29 April

Read all the latest news from the marcomms world including updates from Omnicom Media Group Amagi, Virtue Worldwide, Social Beat, and more, in our weekly round-up of people moves and account wins.

3 hours ago

‘A significant shift in the platform's monetisation ...

YouTube’s latest array of affiliate marketing tools stand to put authenticity at the forefront of creators' relationships with brands to create more engaged audiences in return.

3 hours ago

When creativity clashes: The ongoing battle for IP ...

SOUNDING BOARD: Independent advertising agency Bang in the Middle recently accused Medanta of idea theft, sparking a renewed debate over the rights and wrongs in client-agency relationships. Campaign speaks to industry experts on whether the agency's decision to pursue legal action is justified.